PaldiSpot Test
Strain Identification
AVAILABLE THROUGH BIOCENTAUR APPROVED CLINICIANS.
Pricing: £800.00Overview
The PaldiSpot test detects and quantifies Borrelia, Babesia, and Bartonella genospecies in a patient’s DNA. Working from our international world-class facilities, our scientists use a highly sensitive molecular biology technique known as quantitative polymerase chain reaction (qPCR) to analyse DNA extracted from a blood sample. This advanced method screens for the presence of 24 of the most common strains of Borrelia, Babesia, and Bartonella genospecies with exceptional precision.
For patients with a positive Lyme disease diagnosis within the last 6 months, the PaldiSpot test provides critical information that can inform the development of personalised treatment and therapy plans for Lyme disease and related co-infections — helping clinicians make more informed decisions and improving patient outcomes.
The PaldiSpot test is clinically validated and highly accurate. It is suitable for adults aged 18 and over. Results are processed and returned within 14 business days.
Purpose of The Test
The PaldiSpot test analyses DNA extracted from blood cells and serum to screen for 24 of the most common Borrelia, Babesia, and Bartonella genospecies.
During the testing process, the patient’s DNA is used in quantitative polymerase chain reaction (qPCR) — an advanced laboratory method that amplifies and measures specific DNA sequences in real time. Each sample is examined for the genetic signatures of 24 target strains.
To ensure the highest level of reliability, all reactions are performed in triplicate, with both positive and negative controls conducted for every strain tested.
The final PaldiSpot report indicates whether a specific strain is present in the patient’s cells or serum and includes a quantification parameter known as the Ct value (cycle threshold), which reflects the detected genetic load.
Lyme Disease-associated species
Lyme disease is a bacterial infection that can be transmitted to humans by a bite from an infected tick. It is usually easier to treat when it is diagnosed early. If left untreated, there is a risk that a person may develop severe or long-lasting symptoms.
People with Lyme disease react differently to the condition and the symptoms can vary in type and severity. Most people with early symptoms of Lyme disease will develop a flat, circular red rash around the bite, usually within four weeks of being bitten. Not everyone with Lyme disease will develop a rash. Some people experience flu-like symptoms including a high temperature, tiredness, headaches and muscle and/or joint pain.
A blood test is usually used to confirm Lyme disease but it can be difficult to diagnose.
Scientific Background
The PaldiSpot test is based on quantitative polymerase chain reaction (qPCR) — a highly sensitive molecular biology technique that allows scientists to detect and measure even the smallest quantities of genetic material. qPCR works by amplifying specific DNA sequences in real time, which enables precise identification of microbial DNA in a patient’s sample.
In the PaldiSpot test, DNA is extracted from blood cells and serum, then analysed for 24 of the most clinically relevant Borrelia, Babesia, and Bartonella genospecies — pathogens commonly linked to Lyme disease and associated co-infections. Each reaction is performed in triplicate, with positive and negative controls included for every strain to ensure reproducibility and diagnostic accuracy.
The test measures amplification cycles to generate a Ct value (cycle threshold), which reflects the relative amount of microbial DNA present in the sample. This allows clinicians not only to confirm the presence of infection but also to estimate pathogen load, providing valuable insight into disease activity and progression.
When to Consider the Test
The PaldiSpot test is typically recommended for patients with a clinical diagnosis of Lyme disease or related co-infections within the last 6 months, particularly those presenting with compatible symptoms or a documented history of exposure, such as a tick bite.
Please note: To be eligible for the PaldiSpot test, you must have received a positive diagnostic test result for Lyme disease within the last six months.
It may also be used:
- Alongside the PrimeSpot test, to provide a broader assessment of infections linked to Lyme disease and chronic fatigue syndromes.
- Following inconclusive or negative standard serological tests, to provide additional molecular evidence.
- For monitoring, to evaluate the effectiveness of treatment or track disease progression.
At this time, the PaldiSpot test is not designed for preventive screening in asymptomatic individuals or for general population testing.
Samples & Processing
Once the test is ordered, your Biocentaur approved clinician will be provided with a PaldiSpot collection kit, which includes:
- Step-by-step instructions for collecting a blood sample.
- Secure packaging for sample protection.
- Details on how to return your sample to our laboratory.
Once received, your sample is processed under strict internal quality controls.
Results are typically available within 14 business days from the date the sample arrives at our facility. All analyses are performed using validated molecular and biochemical techniques in Biocentaur’s certified laboratories, ensuring the highest standards of accuracy and reproducibility.
Result Interpretation
If you would like more information about the PaldiSpot test or any of the Biocentaur range of advanced genetic diagnostics, please visit our FAQs page or contact us directly.
Why Choose PaldiSpot Test
The PaldiSpot test is developed by the same team of scientists behind Biocentaur’s clinically validated cancer diagnostics. Our expertise in precision medicine, molecular biology, and genetic analysis ensures reliable results and cutting-edge accuracy.
We bring the same scientific integrity and standard of clinical excellence that underpin our oncology research to the detection of infectious diseases such as Lyme disease — offering patients and clinicians a test they can trust.
Good to know: The PaldiSpot test can only be ordered through an approved medical clinician and is not available for direct purchase by patients. If you do not currently have a clinician, contact us via our contact form and our clinical team will connect you with a Biocentaur-approved medical clinician.